Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial.

Thyroid · 2019 · PMC6918875 · PMID 31860408

Europe PMC DOI

hedged sentence

0.2273

closest p · 4.5× alpha

0.2273

boldest claim

The sentences

a nonsignificant trendp = 0.2273not close (p > 0.1)

There was a nonsignificant trend for more early DMTs in patients with sarcopenia compared with those without sarcopenia (55.3% vs. 44.7%, respectively; p = 0.2273).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.